Page 403 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 20 Melanoma 381

185. Paoloni M, Mazcko C, Selting K, et al.: Defining the pharmacody- 200. de Vries TJ, Smeets M, de GR, et al.: Expression of gp100, MART-
namic profile and therapeutic index of nhs-il12 immunocytokine 1, tyrosinase, and S100 in paraffin-embedded primary melanomas
in dogs with malignant melanoma, PLoS One 10:e0129954, 2015. and locoregional, lymph node, and visceral metastases: implica-
VetBooks.ir 186. Rossi UA, Gil-Cardeza ML, Villaverde MS, et al.: Interferon-beta tions for diagnosis and immunotherapy. A study conducted by the
EORTC Melanoma Cooperative Group, J Pathol 193:13–20, 2001.
gene transfer induces a strong cytotoxic bystander effect on mela-
noma cells, Biomed Pharmacother 72:44–51, 2015.
187. Finocchiaro LM, Fondello C, Gil-Cardeza ML, et al.: Cytokine- 201. Gradilone A, Gazzaniga P, Ribuffo D, et al.: Prognostic signifi-
cance of tyrosinase expression in sentinel lymph node biopsy for
enhanced vaccine and interferon-beta plus suicide gene therapy as ultra-thin, thin, and thick melanomas, Eur Rev Med Pharmacol Sci
surgery adjuvant treatments for spontaneous canine melanoma, 16:1367–1376, 2012.
Hum Gene Ther 26:367–376, 2015. 202. Liao JC, Gregor P, Wolchok JD, et al.: Vaccination with human
188. Riccardo F, Iussich S, Maniscalco L, et al.: CSPG4-specific immu- tyrosinase DNA induces antibody responses in dogs with advanced
nity and survival prolongation in dogs with oral malignant mela- melanoma, Cancer Immun 6(8), 2006.
noma immunized with human CSPG4 DNA, Clin Cancer Res 203. Goubier A, Fuhrmann L, Forest L, et al.: Superiority of needle-free
20:3753–3762, 2014. transdermal plasmid delivery for the induction of antigen-specific
189. Westberg S, Sadeghi A, Svensson E, et al.: Treatment efficacy and IFNgamma T cell responses in the dog, Vaccine 26:2186–2190, 2008.
immune stimulation by AdCD40L gene therapy of spontaneous 204. Grosenbaugh DA, Leard AT, Bergman PJ, et al.: Safety and efficacy
canine malignant melanoma, J Immunother 36:350–358, 2013. of a xenogeneic DNA vaccine encoding for human tyrosinase as
190. Horiuchi Y, Tominaga M, Ichikawa M, et al.: Relationship between adjunctive treatment for oral malignant melanoma in dogs follow-
regulatory and type 1 T cells in dogs with oral malignant mela- ing surgical excision of the primary tumor, Am J Vet Res 72:1631–
noma, Microbiol Immunol 54:152–159, 2010. 1638, 2011.
191. Tominaga M, Horiuchi Y, Ichikawa M, et al.: Flow cytometric 205. Ottnod JM, Smedley RC, Walshaw R, et al.: A retrospective analysis
analysis of peripheral blood and tumor-infiltrating regulatory T of the efficacy of Oncept vaccine for the adjunct treatment of canine
cells in dogs with oral malignant melanoma, J Vet Diagn Invest oral malignant melanoma, Vet Comp Oncol 11:219–229, 2013.
22:438–441, 2010. 206. Verganti S, Berlato D, Blackwood L, et al.: Use of Oncept mela-
192. Fortuna L, Relf J, Chang YM, et al.: Prevalence of FoxP3(+) Cells noma vaccine in 69 canine oral malignant melanomas in the UK,
in canine tumours and lymph nodes correlates positively with glu- J Small Anim Pract 58:10–16, 2017.
cose transporter 1 expression, J Comp Pathol 155:171–180, 2016. 207. Treggiari E, Grant JP, North SM: A retrospective review of out-
193. Pinheiro D, Chang YM, Bryant H, et al.: Dissecting the regula- come and survival following surgery and adjuvant xenogeneic
tory microenvironment of a large animal model of non-Hodgkin DNA vaccination in 32 dogs with oral malignant melanoma, J Vet
lymphoma: evidence of a negative prognostic impact of FOXP3+ T Med Sci 78:845–850, 2016.
cells in canine B cell lymphoma, PLoS One 9:e105027, 2014. 208. McLean JL, Lobetti RG: Use of the melanoma vaccine in 38 dogs:
194. Guevara-Patino JA, Turk MJ, Wolchok JD, et al.: Immunity to can- the South African experience, J South AfrV et Assoc 86:1246, 2015.
cer through immune recognition of altered self: studies with mela- 209. Herzog A, Buchholz J, Ruess-Melzer K, et al.: Concurrent irradia-
noma, Adv Cancer Res 90:157–177, 2003. tion and DNA tumor vaccination in canine oral malignant mela-
195. Bergman PJ, Camps-Palau MA, McKnight JA, et al.: Development noma: a pilot study, Schweiz Arch Tierheilkd 155:135–142, 2013.
of a xenogeneic DNA vaccine program for canine malignant mela- 210. Sarbu L, Kitchell BE, Bergman PJ: Safety of administering the canine
noma at the Animal Medical Center, Vaccine 24:4582–4585, 2006. melanoma DNA vaccine (Oncept) to cats with malignant melanoma
196. Bergman PJ, McKnight J, Novosad A, et al.: Long-term survival of - a retrospective study, J Feline Med Surg 19:224–230, 2017.
dogs with advanced malignant melanoma after DNA vaccination 211. Perales MA, Yuan J, Powel S, et al.: Phase I/II study of GM-CSF
with xenogeneic human tyrosinase: a phase I trial, Clin Cancer Res DNA as an adjuvant for a multipeptide cancer vaccine in patients
9:1284–1290, 2003. with advanced melanoma, Mol Ther 16:2022–2029, 2008.
197. Wolchok JD, Yuan J, Houghton AN, et al.: Safety and immunoge- 212. Yuan J, Ku GY, Gallardo HF, et al.: Safety and immunogenicity
nicity of tyrosinase DNA vaccines in patients with melanoma, Mol of a human and mouse gp100 DNA vaccine in a phase I trial of
Ther 15:2044–2050, 2007. patients with melanoma, Cancer Immun 9(5), 2009.
198. Phillips JC, Lembcke LM, Noltenius CE, et al.: Evaluation of 213. Riccardo F, Iussich S, Maniscalco L, et al.: CSPG4-specific immu-
tyrosinase expression in canine and equine melanocytic tumors, Am nity and survival prolongation in dogs with oral malignant mela-
J Vet Res 73:272–278, 2012. noma immunized with human CSPG4 DNA, Clin Cancer Res
199. Cangul IT, van Garderen E, van der Poel HJ, et al.: Tyrosinase 20:3753–3762, 2014.
gene expression in clear cell sarcoma indicates a melanocytic origin: 214. Manley CA, Leibman NF, Wolchok JD, et al.: Xenogeneic murine
insight from the first reported canine case, APMIS JID - 8803400 tyrosinase DNA vaccine for malignant melanoma of the digit of
107:982–988, 1999. dogs, J Vet Intern Med 25:94–99, 2011.